Breaking News

C2 Pharma Expands Ophthalmic API Portfolio

Launches Naphazoline Hydrochloride that will be produced by CMO partner SMS Lifesciences.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

C2 PHARMA, a global provider of ophthalmic and niche active pharmaceutical ingredients (APIs), has launched its latest API, Naphazoline Hydrochloride. The validation campaign for Naphazoline HCL was completed in June 2024. A Certificate of Suitability (CEP) is under approval while the US-Drug Master File (US-DMF) is planned for submission by November 2024 and the API dossier for Brazil (DIFA) in December 2024.   Naphazoline HCL is effective in alleviating red eyes and nasal congestion, making ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters